| 袁世发,刘彩霞,刘志军,等.贝伐珠单抗、雷替曲塞联合奥沙利铂治疗晚期结直肠癌 45例[J].安徽医药,2025,29(9):1887-1890. |
| 贝伐珠单抗、雷替曲塞联合奥沙利铂治疗晚期结直肠癌 45例 |
| Efficacy of bevacizumab and raltitrexed combined with oxaliplatin in the treatment of advanced colorectal cancer:an analysis of 45 cases |
| |
| DOI：10.3969/j.issn.1009-6469.2025.09.040 |
| 中文关键词: 结直肠癌 贝伐珠单抗 雷替曲塞 奥沙利铂 P53抗体 |
| 英文关键词: Colorectal cancer Bevacizumab Raltitrexed Oxaliplatin P53 antibody |
| 基金项目:河北省医学科学研究重点课题( 20160188) |
|
| 摘要点击次数: 231 |
| 全文下载次数: 327 |
| 中文摘要: |
| 目的比较贝伐珠单抗、雷替曲塞联合奥沙利铂治疗晚期结直肠癌的效果。方法选择 2020年 12月至 2022年 1月在中国人民武装警察部队河北省总队医院与河北医科大学第四医院接受治疗的 90例晚期结直肠癌病人，依据不同治疗方案分为观察组与对照组，每组各 45例。两组均接受临床常规治疗，对照组采用雷替曲塞联合奥沙利铂治疗，观察组采用贝伐珠单抗与雷替曲塞、奥沙利铂治疗。比较两组治疗后有效率、 1年生存率、疾病进展时间、 P53抗体水平、不良反应发生情况。结经过治疗后，观察组总有效率 66.67%较对照组 44.44%明显提高( P<0.05)。经过治疗后，观察组 1年生存率 55.56%显著高果于对照组 31.11%(log rank χ2=8.18，P<0.05)；对比 P53抗体水平，观察组显著低于对照组( P<0.05)；在不良反应发生方面，两组腹泻、周围神经毒性、转氨酶升高、贫血、脱发等情况差异无统计学意义(P>0.05)，观察组恶心呕吐、白细胞降低、血小板减少发生率显著低于对照组(P<0.05)。结论对晚期结直肠癌给予贝伐珠单抗 +雷替曲塞 +奥沙利铂治疗，可有效延长病人生存时间，效果较为理想，临床应用价值较高。 |
| 英文摘要: |
| Objective To analyze and compare the efficacies of bevacizumab and raltitrexed combined with oxaliplatin in the treat-ment of advanced colorectal cancer patients.Methods A total of 90 patients with advanced colorectal cancer, who received treatmentin Hebei General Hospital of Armed Police Force, People's Armed Police Force of China from December 2020 to January 2022, wereselected and assigned into two groups (observation group and control group) according to different treatment plans, with 45 cases ineach group. All patients received conventional clinical treatment. On this basis, the control group was treated with raltitrexed combinedwith oxaliplatin, while the observation group was treated with bevacizumab, raltitrexed and oxaliplatin. The effective rate, one-year sur-vival time, disease progression time, P53 antibody level, and adverse reactions were compared between the two groups after treatment.Results After treatment, the total effective rate of the observation group was significantly higher than that of the control group (66.67% vs. 44.44%; P<0.05). The one-year survival rate of the observation group was significantly higher than that of the control group (55.56% vs. 31.11%) (log rank χ2=8.18, P<0.05). The level of P53 antibody in the observation group was obviously lower than that in the control group (P<0.05); in terms of adverse reactions, there was no obvious difference between the two groups in terms of diarrhea,peripheral neurotoxicity, elevated transaminases, anemia, and hair loss (P>0.05), while the incidences of nausea, vomiting, leukopenia,and thrombocytopenia in the observation group were obviously lower than those in the control group (P<0.05).Conclusion In patientswith advanced colorectal cancer, the therapy of bevacizumab and raltitrexed combined with oxaliplatin can effectively prolong the sur-vival with satisfactory efficacy, indicating high clinical application value. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
